A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Barbara Eichhorst; Carsten Utoft Niemann; Arnon P.  Kater; Moritz Fürstenau; Julia  Von Tresckow; Can Zhang; Sandra Robrecht; Michael  Gregor; Gunnar  Juliusson; Patrick  Thornton; Philipp B.  Staber; Tamar Tadmor; Vesa  Lindström; Caspar da Cunha-Bang; Christof  Schneider; Christian Bjørn Poulsen; Thomas Thomas Illmer; Björn  Schöttker; Ann  Janssens; Ilse Christiansen; Thomas  Noesslinger; Michael  Baumann; Marjolein  van der Klift; Ulrich Jaeer Jaeger; Henrik Frederiksen; Maria  B.L. Leijs; Mels Hoogendoorn; Kourosh  Lotfi; Holger  Hebart; Tobias Gaska; Harry R. Koene; Florian  Simon; Nisha De Silva; Anna-Maria  Fink; Kirsten  Fischer; Clemens-Martin Wendtner; Karl-Anton  Kreuzer; Matthias  Ritgen; Monika Brüggemann Brüggemann; Eugen  Tausch; Mark-David Levin; Marinus H J van Oers; Christian Hartmann Geisler; Stephan  Stilgenbauer; Michael  Hallek

doi:10.1182/blood-2021-146161

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater, Moritz Fürstenau, Julia Von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse ChristiansenThomas Noesslinger, Michael Baumann, Marjolein van der Klift, Ulrich Jaeer Jaeger, Henrik Frederiksen, Maria B.L. Leijs, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry R. Koene, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Monika Brüggemann Brüggemann, Eugen Tausch, Mark-David Levin, Marinus H J van Oers, Christian Hartmann Geisler, Stephan Stilgenbauer, Michael Hallek

KI, OUH, Forskningsenhed for Hæmatologi (Odense)

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Tidsskrift	Blood
Vol/bind	138
Udgave nummer	Supplement 1
Sider (fra-til)	71
ISSN	0006-4971
DOI	https://doi.org/10.1182/blood-2021-146161
Status	Udgivet - nov. 2021
Begivenhed	63rd ASH Annual Meeting. - Georgia World Congress Center and Virtual, Atlanta, USA Varighed: 11. dec. 2021 → 14. dec. 2021

Konference

Konference	63rd ASH Annual Meeting.
Lokation	Georgia World Congress Center and Virtual
Land/Område	USA
By	Atlanta
Periode	11/12/2021 → 14/12/2021

Dokumenter og links

10.1182/blood-2021-146161

Citationsformater

Eichhorst, B., Niemann, C. U., Kater, A. P., Fürstenau, M., Von Tresckow, J., Zhang, C., Robrecht, S., Gregor, M., Juliusson, G., Thornton, P., Staber, P. B., Tadmor, T., Lindström, V., da Cunha-Bang, C., Schneider, C., Poulsen, C. B., Thomas Illmer, T., Schöttker, B., Janssens, A., ... Hallek, M. (2021). A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. Blood, 138(Supplement 1), 71. https://doi.org/10.1182/blood-2021-146161

Eichhorst, Barbara ; Niemann, Carsten Utoft ; Kater, Arnon P. et al. / A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. I: Blood. 2021 ; Bind 138, Nr. Supplement 1. s. 71.

@article{fca2ae81daf74cd68e83f4a2a71437b8,

title = "A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial",

author = "Barbara Eichhorst and Niemann, {Carsten Utoft} and Kater, {Arnon P.} and Moritz F{\"u}rstenau and {Von Tresckow}, Julia and Can Zhang and Sandra Robrecht and Michael Gregor and Gunnar Juliusson and Patrick Thornton and Staber, {Philipp B.} and Tamar Tadmor and Vesa Lindstr{\"o}m and {da Cunha-Bang}, Caspar and Christof Schneider and Poulsen, {Christian Bj{\o}rn} and {Thomas Illmer}, Thomas and Bj{\"o}rn Sch{\"o}ttker and Ann Janssens and Ilse Christiansen and Thomas Noesslinger and Michael Baumann and {van der Klift}, Marjolein and Jaeger, {Ulrich Jaeer} and Henrik Frederiksen and {B.L. Leijs}, Maria and Mels Hoogendoorn and Kourosh Lotfi and Holger Hebart and Tobias Gaska and Koene, {Harry R.} and Florian Simon and {De Silva}, Nisha and Anna-Maria Fink and Kirsten Fischer and {Clemens-Martin Wendtner} and Karl-Anton Kreuzer and Matthias Ritgen and Br{\"u}ggemann, {Monika Br{\"u}ggemann} and Eugen Tausch and Mark-David Levin and {van Oers}, {Marinus H J} and Geisler, {Christian Hartmann} and Stephan Stilgenbauer and Michael Hallek",

year = "2021",

month = nov,

doi = "10.1182/blood-2021-146161",

language = "English",

volume = "138",

pages = "71",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "Supplement 1",

note = "63rd ASH Annual Meeting. ; Conference date: 11-12-2021 Through 14-12-2021",

}

Eichhorst, B, Niemann, CU, Kater, AP, Fürstenau, M, Von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, PB, Tadmor, T, Lindström, V, da Cunha-Bang, C, Schneider, C, Poulsen, CB, Thomas Illmer, T, Schöttker, B, Janssens, A, Christiansen, I, Noesslinger, T, Baumann, M, van der Klift, M, Jaeger, UJ, Frederiksen, H, B.L. Leijs, M, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, HR, Simon, F, De Silva, N, Fink, A-M, Fischer, K, Clemens-Martin Wendtner, Kreuzer, K-A, Ritgen, M, Brüggemann, MB, Tausch, E, Levin, M-D, van Oers, MHJ, Geisler, CH, Stilgenbauer, S & Hallek, M 2021, 'A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial', Blood, bind 138, nr. Supplement 1, s. 71. https://doi.org/10.1182/blood-2021-146161

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. / Eichhorst, Barbara; Niemann, Carsten Utoft; Kater, Arnon P. et al.

I: Blood, Bind 138, Nr. Supplement 1, 11.2021, s. 71.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

AU - Eichhorst, Barbara

AU - Niemann, Carsten Utoft

AU - Kater, Arnon P.

AU - Fürstenau, Moritz

AU - Von Tresckow, Julia

AU - Zhang, Can

AU - Robrecht, Sandra

AU - Gregor, Michael

AU - Juliusson, Gunnar

AU - Thornton, Patrick

AU - Staber, Philipp B.

AU - Tadmor, Tamar

AU - Lindström, Vesa

AU - da Cunha-Bang, Caspar

AU - Schneider, Christof

AU - Poulsen, Christian Bjørn

AU - Thomas Illmer, Thomas

AU - Schöttker, Björn

AU - Janssens, Ann

AU - Christiansen, Ilse

AU - Noesslinger, Thomas

AU - Baumann, Michael

AU - van der Klift, Marjolein

AU - Jaeger, Ulrich Jaeer

AU - Frederiksen, Henrik

AU - B.L. Leijs, Maria

AU - Hoogendoorn, Mels

AU - Lotfi, Kourosh

AU - Hebart, Holger

AU - Gaska, Tobias

AU - Koene, Harry R.

AU - Simon, Florian

AU - De Silva, Nisha

AU - Fink, Anna-Maria

AU - Fischer, Kirsten

AU - Clemens-Martin Wendtner,

AU - Kreuzer, Karl-Anton

AU - Ritgen, Matthias

AU - Brüggemann, Monika Brüggemann

AU - Tausch, Eugen

AU - Levin, Mark-David

AU - van Oers, Marinus H J

AU - Geisler, Christian Hartmann

AU - Stilgenbauer, Stephan

AU - Hallek, Michael

PY - 2021/11

Y1 - 2021/11

U2 - 10.1182/blood-2021-146161

DO - 10.1182/blood-2021-146161

M3 - Conference abstract in journal

SN - 0006-4971

VL - 138

SP - 71

JO - Blood

JF - Blood

IS - Supplement 1

T2 - 63rd ASH Annual Meeting.

Y2 - 11 December 2021 through 14 December 2021

ER -

Eichhorst B, Niemann CU, Kater AP, Fürstenau M, Von Tresckow J, Zhang C et al. A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. Blood. 2021 nov.;138(Supplement 1):71. doi: 10.1182/blood-2021-146161